Erratum: Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: A randomized phase II trial by the prostate cancer clinical trials consortium (Investigational New Drugs DOI: 10.1007/s10637-010-9420-8)

Deborah A. Bradley; Stephanie Daignault; Charles J. Ryan; Robert S. DiPaola; Kathleen A. Cooney; David C. Smith; Eric Small; Paul Mathew; Mitchell E. Gross; Mark N. Stein; Alice Chen; Kenneth J. Pienta; June Escara-Wilke; Gerald Doyle; Mahmoud Al-Hawary; Evan T. Keller; Maha Hussain

doi:10.1007/s10637-010-9502-7

Erratum: Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: A randomized phase II trial by the prostate cancer clinical trials consortium (Investigational New Drugs DOI: 10.1007/s10637-010-9420-8)

Deborah A. Bradley, Stephanie Daignault, Charles J. Ryan, Robert S. DiPaola, Kathleen A. Cooney, David C. Smith, Eric Small, Paul Mathew, Mitchell E. Gross, Mark N. Stein, Alice Chen, Kenneth J. Pienta, June Escara-Wilke, Gerald Doyle, Mahmoud Al-Hawary, Evan T. Keller, Maha Hussain

Research output: Contribution to journal › Comment/debate

Original language	English
Pages (from-to)	1517-1518
Number of pages	2
Journal	Investigational New Drugs
Volume	29
Issue number	6
DOIs	https://doi.org/10.1007/s10637-010-9502-7
State	Published - Dec 2011

ASJC Scopus subject areas

Oncology
Pharmacology
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s10637-010-9502-7

Fingerprint

Dive into the research topics of 'Erratum: Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: A randomized phase II trial by the prostate cancer clinical trials consortium (Investigational New Drugs DOI: 10.1007/s10637-010-9420-8)'. Together they form a unique fingerprint.

Cite this

Bradley, D. A., Daignault, S., Ryan, C. J., DiPaola, R. S., Cooney, K. A., Smith, D. C., Small, E., Mathew, P., Gross, M. E., Stein, M. N., Chen, A., Pienta, K. J., Escara-Wilke, J., Doyle, G., Al-Hawary, M., Keller, E. T., & Hussain, M. (2011). Erratum: Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: A randomized phase II trial by the prostate cancer clinical trials consortium (Investigational New Drugs DOI: 10.1007/s10637-010-9420-8). Investigational New Drugs, 29(6), 1517-1518. https://doi.org/10.1007/s10637-010-9502-7

Bradley, Deborah A. ; Daignault, Stephanie ; Ryan, Charles J. et al. / Erratum : Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: A randomized phase II trial by the prostate cancer clinical trials consortium (Investigational New Drugs DOI: 10.1007/s10637-010-9420-8). In: Investigational New Drugs. 2011 ; Vol. 29, No. 6. pp. 1517-1518.

@article{e46c76b49d2c4695b4954c93a2b5f506,

title = "Erratum: Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: A randomized phase II trial by the prostate cancer clinical trials consortium (Investigational New Drugs DOI: 10.1007/s10637-010-9420-8)",

author = "Bradley, {Deborah A.} and Stephanie Daignault and Ryan, {Charles J.} and DiPaola, {Robert S.} and Cooney, {Kathleen A.} and Smith, {David C.} and Eric Small and Paul Mathew and Gross, {Mitchell E.} and Stein, {Mark N.} and Alice Chen and Pienta, {Kenneth J.} and June Escara-Wilke and Gerald Doyle and Mahmoud Al-Hawary and Keller, {Evan T.} and Maha Hussain",

year = "2011",

month = dec,

doi = "10.1007/s10637-010-9502-7",

language = "English",

volume = "29",

pages = "1517--1518",

number = "6",

}

Bradley, DA, Daignault, S, Ryan, CJ, DiPaola, RS, Cooney, KA, Smith, DC, Small, E, Mathew, P, Gross, ME, Stein, MN, Chen, A, Pienta, KJ, Escara-Wilke, J, Doyle, G, Al-Hawary, M, Keller, ET & Hussain, M 2011, 'Erratum: Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: A randomized phase II trial by the prostate cancer clinical trials consortium (Investigational New Drugs DOI: 10.1007/s10637-010-9420-8)', Investigational New Drugs, vol. 29, no. 6, pp. 1517-1518. https://doi.org/10.1007/s10637-010-9502-7

Erratum: Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: A randomized phase II trial by the prostate cancer clinical trials consortium (Investigational New Drugs DOI: 10.1007/s10637-010-9420-8). / Bradley, Deborah A.; Daignault, Stephanie; Ryan, Charles J. et al.
In: Investigational New Drugs, Vol. 29, No. 6, 12.2011, p. 1517-1518.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Erratum

T2 - Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: A randomized phase II trial by the prostate cancer clinical trials consortium (Investigational New Drugs DOI: 10.1007/s10637-010-9420-8)

AU - Bradley, Deborah A.

AU - Daignault, Stephanie

AU - Ryan, Charles J.

AU - DiPaola, Robert S.

AU - Cooney, Kathleen A.

AU - Smith, David C.

AU - Small, Eric

AU - Mathew, Paul

AU - Gross, Mitchell E.

AU - Stein, Mark N.

AU - Chen, Alice

AU - Pienta, Kenneth J.

AU - Escara-Wilke, June

AU - Doyle, Gerald

AU - Al-Hawary, Mahmoud

AU - Keller, Evan T.

AU - Hussain, Maha

PY - 2011/12

Y1 - 2011/12

UR - http://www.scopus.com/inward/record.url?scp=84861610197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861610197&partnerID=8YFLogxK

U2 - 10.1007/s10637-010-9502-7

DO - 10.1007/s10637-010-9502-7

M3 - Comment/debate

AN - SCOPUS:84861610197

SN - 0167-6997

VL - 29

SP - 1517

EP - 1518

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 6

ER -

Bradley DA, Daignault S, Ryan CJ, DiPaola RS, Cooney KA, Smith DC et al. Erratum: Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: A randomized phase II trial by the prostate cancer clinical trials consortium (Investigational New Drugs DOI: 10.1007/s10637-010-9420-8). Investigational New Drugs. 2011 Dec;29(6):1517-1518. doi: 10.1007/s10637-010-9502-7

Erratum: Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: A randomized phase II trial by the prostate cancer clinical trials consortium (Investigational New Drugs DOI: 10.1007/s10637-010-9420-8)

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this